Tertiary lymphoid tissue in the tumor microenvironment: From its occurrence to immunotherapeutic implications

International Reviews of Immunology

Volumn 34, Issue 2, 2015, Pages 123-133

  Di Caro, Giuseppe ^a   Castino, Giovanni Francesco ^a   Bergomas, Francesca ^a   Cortese, Nina ^a   Chiriva Internati, Maurizio ^b   Grizzi, Fabio ^a   Mantovani, Alberto ^a   Marchesi, Federica ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Immune infiltration; Prognosis; Tertiary Lymphoid Tissue

Indexed keywords

CXCL13 CHEMOKINE; FIBROBLAST GROWTH FACTOR 2; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SECONDARY LYMPHOID TISSUE CHEMOKINE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOCYTIC INFILTRATION; LYMPHOID TISSUE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL MOTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; NEOPLASMS; TRANSPLANTATION;

ANIMALS; CELL MOVEMENT; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84928559983     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2015.1018416     Document Type: Review

References (70)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow Lancet 2001;357:539-545.
3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444.
4. VeselyMD, KershawMH, Schreiber RD, SmythMJ.Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-271.
5. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-1570.
6. Di Caro G, Marchesi F, Laghi L, Grizzi F. Immune cells: plastic players along colorectal cancer progression. J CellMolMed 2013;17:1088-1095.
7. Galon J, Pages F, Marincola FM, et al.Cancer classification using theImmunoscore: aworldwide task force. J TranslMed 2012;10:205.
8. Restifo NP. A "big data" view of the tumor "immunome". Immunity 2013;39:631-632.
9. BindeaG, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoralimmune cells reveal the immune landscape in human cancer. Immunity 2013;39:782-795.
10. Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27:5944-5951.
11. DiCaro G, Marchesi F.Tertiary lymphoid tissue: a gateway forTcells in the tumormicroenvironment. Oncoimmunology 2014;3:e28850.
12. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-489.
13. Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol 2013;31:137-161.
14. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006;6:205-217.
15. Carragher DM, Rangel-Moreno J, Randall TD. Ectopic lymphoid tissues and local immunity. Semin Immunol 2008;20:26-42.
16. Neyt K, Perros F, GeurtsvanKesselCH, et al.Tertiary lymphoid organs ininfection and autoimmunity. Trends Immunol 2012;33:297-305.
17. de Chaisemartin L, Goc J, Damotte D, et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 2011;71:6391-6399.
18. Di Caro G, Bergomas F, Grizzi F, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res 2014;20:2147-2158.
19. Lutz ER, Wu AA, BigelowE, et al.Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014;2:616-631.
20. Futterer A, Mink K, Luz A, et al. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 1998;9:59-70.
21. Randall TD, Carragher DM, Rangel-Moreno J. Development of secondary lymphoid organs. Annu Rev Immunol 2008;26:627-650.
22. Cupedo T, Vondenhoff MF, Heeregrave EJ, et al. Presumptive lymph node organizers are differentially represented in developing mesenteric and peripheral nodes. J Immunol 2004;173:2968-2975.
23. Roozendaal R, Mebius RE. Stromal cell-immune cell interactions.AnnuRevImmunol 2011;29:23-43.
24. Peduto L, Dulauroy S, Lochner M, et al. Inflammation recapitulates the ontogeny of lymphoid stromal cells. J Immunol 2009;182:5789-5799.
25. Kratz A, Campos-Neto A, Hanson MS, Ruddle NH. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 1996;183:1461-1472.
26. Hjelmstrom P, Fjell J, Nakagawa T, et al. Lymphoid tissue homing chemokines are expressed in chronic inflammation. Am J Pathol 2000;156:1133-1138.
27. Martin AP, Coronel EC, Sano G, et al. A novel model for lymphocytic infiltration of the thyroid gland generated by transgenic expression of the CC chemokine CCL21. J Immunol 2004;173:4791-4798.
28. Furtado GC, Marinkovic T, Martin AP, et al. Lymphotoxin beta receptor signaling is required for inflammatory lymphangiogenesis in the thyroid. Proc Natl Acad Sci USA 2007;104:5026-5031.
29. Marchesi F, Martin AP, Thirunarayanan N, et al. CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles. Mucosal Immunol 2009;2:486-494.
30. Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, et al. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc Natl Acad Sci USA 2007;104:10577-10582.
31. Furtado GC, Marinkovic T, Martin AP, et al. Lymphotoxin beta receptor signaling is required for inflammatory lymphangiogenesis in the thyroid. Proc Natl Acad Sci USA 2007;104:5026-5031.
32. Ruddle NH. Lymphatic vessels and tertiary lymphoid organs. J Clin Invest 2014;124:953-959.
33. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin.NEngl JMed 2000;343:1020-1034.
34. VondenhoffMF, Greuter M, Goverse G, et al. LTbetaR signaling induces cytokine expression and upregulates lymphangiogenic factors in lymph node anlagen. J Immunol 2009;182:5439-5445.
35. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010;140:460-476.
36. Muniz LR, Pacer ME, Lira SA, Furtado GC. A critical role for dendritic cells in the formation of lymphatic vessels within tertiary lymphoid structures. J Immunol 2011;187:828-834.
37. Liao S, Ruddle NH. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J Immunol 2006;177:3369-3379.
38. Martinet L, Garrido I, Filleron T, et al. Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011;71:5678-5687.
39. Dieu-Nosjean MC, Goc J, Giraldo NA, et al. Tertiary lymphoid structures in cancer and beyond. Trends Immunol 2014;35(11):571-580.
40. Junt T, Scandella E, Ludewig B. Formfollows function: lymphoid tissuemicroarchitecture in antimicrobial immune defence. Nat Rev Immunol 2008;8:764-775.
41. Gajewski TF, Woo SR, Zha Y, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumormicroenvironment. Curr Opin Immunol 2013;25:268-276.
42. Yu P, Lee Y, Liu W, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004;5:141-149.
43. Tamada K, Shimozaki K, Chapoval AI, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000;6:283-289.
44. MlecnikB, BindeaG, Pages F, Galon J. Tumorimmunosurveillance in human cancers.CancerMetastasis Rev 2011;30:5-12.
45. Spratt JSJ, Spjut HJ. Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma. Cancer 1967;20:1976-1985.
46. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987;1:1303-1306.
47. Graham DM, Appelman HD. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator.Mod Pathol 1990;3:332-335.
48. Ogino S, Nosho K, IraharaN, et al. Lymphocytic reaction to colorectal cancer is associatedwith longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009;15:6412-6420.
49. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964.
50. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26:4410-4417.
51. Goc J, Fridman WH, Sautes-Fridman C, Dieu-Nosjean MC. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2013;2(12):e26836.
52. Germain C, Gnjatic S, Tamzalit F, et al. Presence of B Cells in tertiary lymphoid structures is associated with a protective immunity in lung cancer patients. Am J Respir Crit CareMed 2014;189:832-844.
53. Goc J, Germain C, Vo-Bourgais TK, et al.Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the good positive prognostic value of infiltrating CD8+ T Cells. Cancer Res 2014;74:705-715.
54. Coppola D, Nebozhyn M, Khalil F, et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 2011;179:37-45.
55. Messina JL, Fenstermacher DA, Eschrich S, et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy Sci Rep 2012;2:765.
56. Sharma P, WagnerK, Wolchok JD, Allison JP.Novel cancer immunotherapy agentswith survival benefit: recent successes and next steps. Nat Rev Cancer 2011;11:805-812.
57. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, andmechanistic signatures. Immunity 2013;39:11-26.
58. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-281.
59. Gajewski TF, Schreiber H, Fu YX. Innate and adaptiveimmune cells in the tumormicroenvironment. Nat Immunol 2013;14:1014-1022.
60. Chen L, Taylor JL, Sabins NC, et al. Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther 2013;20:469-477.
61. GeurtsvanKessel CH, Willart MA, Bergen IM, et al. Dendritic cells are crucial formaintenance of tertiary lymphoid structures inthe lung of influenza virus-infectedmice. J Exp Med 2009;206:2339-2349.
62. Mac Keon S, Gazzaniga S, Mallerman J, et al. Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue. Vaccine 2010;28:8162-8168.
63. Veiga-Fernandes H, Coles MC, Foster KE, et al. Tyrosine kinase receptor RET is a key regulator of Peyer's patch organogenesis. Nature 2007;446:547-551.
64. Finn OJ. Cancer immunology. N Engl JMed 2008;358:2704-2715.
65. Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009;69:2000-2009.
66. Gu-TrantienC, Loi S, Garaud S, et al.CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013;123:2873-2892.
67. Martinet L, Filleron T, LeGuellec S, et al.High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin beta-producing dendritic cells in human breast cancer. J Immunol 2013;191:2001-2008.
68. McMullen TP, Lai R, Dabbagh L, et al. Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules. Clin Exp Immunol 2010;161:81-88.
69. Vayrynen JP, Sajanti SA, Klintrup K, et al. Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J Cancer 2014;134:2126-2135.
70. Ladanyi A, Kiss J, Somlai B, et al.Density ofDC-LAMP(+)mature dendritic cells in combinationwith activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007;56:1459-1469.